Analytical Data
-
Gene name
MDC/CCL22
- Application
-
Alternative Names
CCL22; ABCD1; DC/B-CK; SCYA22; STCP1; Chemokine C-C-Motif Ligand 22; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 22; Stimulated T-Cell Chemotactic Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00626
-
Expression Region
Gly25~Gln93
-
Protein Length
Partial
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MDC (CCL22) is a chemokine primarily involved in immune system regulation, particularly in the attraction and activation of immune cells such as T cells and dendritic cells. It plays a crucial role in the immune response by guiding these cells to sites of inflammation and promoting the development of specific immune responses. Research has shown that MDC/CCL22 is associated with various pathological conditions, including cancer, autoimmune diseases, and infectious diseases, where its expression may indicate disease progression or therapeutic outcomes. Studies have also highlighted the potential of MDC/CCL22 as a biomarker for diagnosing and monitoring these conditions. Furthermore, given its pivotal role in the immune system, MDC/CCL22 has garnered interest as a target for novel therapeutic interventions, including immunotherapies and vaccines. Understanding the structure and function of recombinant MDC/CCL22 protein is essential for developing these therapeutics, as it could enhance our ability to manipulate immune responses effectively. The production of recombinant MDC/CCL22 allows for detailed studies of its biological functions and interactions with receptors, providing insights that may lead to innovative treatment strategies for diseases characterized by dysregulated immune responses. As such, the exploration of recombinant MDC/CCL22 protein is crucial for advancing our knowledge of immune regulation and developing targeted therapies.
